Chimerix Inc
NASDAQ:CMRX

Watchlist Manager
Chimerix Inc Logo
Chimerix Inc
NASDAQ:CMRX
Watchlist
Price: 3.02 USD 1% Market Closed
Market Cap: 271.6m USD
Have any thoughts about
Chimerix Inc?
Write Note
CMRX
/
Balance Sheet
/
Other Receivables

Chimerix Inc
Other Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Chimerix Inc
Other Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Chimerix Inc
NASDAQ:CMRX
Other Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Other Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Other Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Chimerix Inc
Glance View

Market Cap
271.6m USD
Industry
Biotechnology

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 87 full-time employees. The company went IPO on 2013-04-11. The firm is focused on discovering, developing and commercializing medicines that address unmet medical needs. The firm offers TEMBEXA (brincidofovir) is an antiviral for the treatment of smallpox in all age groups, including infants, and for patients who have difficulty swallowing. The firm's product Imipridones is a cancer therapies, which provides ONC201 for brain and other cancers, ONC206 for central nervous system cancer and ONC212 for pancreatic cancer and leukemia. The Company’s DSTAT is a glycosaminoglycan derivative of heparin, which is a treatment for hematologic malignancies, including newly diagnosed acute myeloid leukemia (AML) in combination with standard chemotherapy.

CMRX Intrinsic Value
2.98 USD
Overvaluation 1%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Chimerix Inc's Other Receivables?
Other Receivables
0 USD

Based on the financial report for Sep 30, 2024, Chimerix Inc's Other Receivables amounts to 0 USD.

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.